Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Xenon Pharmaceuticals starts XEN801 phase 1 clinical trial
The Clinical Trial Application (CTA) for XEN801 was accepted by Health Canada and the first patient has been dosed in the Phase 1 clinical trial. If supported by
The Clinical Trial Application (CTA) for XEN801 was accepted by Health Canada and the first patient has been dosed in the Phase 1 clinical trial. If supported by
These studies are expected to be completed within the next two months. These studies are anticipated to produce purified recombinant protein and conduct an orthogonal assay to validate
A United States patent entitled "Erythrocytes Containing Arginine Deiminase" has been issued by the U.S. Patent and Trademark Office (USPTO) as U.S. Patent No. 9,125,876. It covers the
Enrolment in the clinical trial is expected to commence in the next few weeks. In its planned Phase 1/2 clinical trial, ESSA intends to demonstrate the safety, tolerability,
The survey was conducted online by Harris Poll on behalf of the CHPA Educational Foundation in February 2015 among 2,002 U.S. adults 18 and older who have used
CVS/pharmacy has expanded the availability of the opioid overdose reversal medicine, naloxone, in several states. The medication was already available at CVS/pharmacy without a prescription in Rhode Island
The joint research and development effort would leverage Purdue Pharma’s intellectual property and lead compounds, combined with AnaBios’ Phase-X technology. Purdue Pharma has more than 10 years of
The state-of-the-art facility provides the translational bridge between pre-clinical development and phase II clinical trials with end-to-end capabilities, including process development, cell banking, cGMP manufacturing, purification and formulation,
The companies initially focused efforts on lung diseases and will now also include kidney diseases. As part of the agreement, SGI will receive royalties and milestones from the
In the ASTRAL-1, ASTRAL-2, and ASTRAL-3 studies, 1,035 patients with genotype 1-6 HCV infection received 12 weeks of SOF/VEL. Among these patients, 21 percent had compensated cirrhosis and